Sodium alendronate
proposal and reliability of indicators
DOI:
https://doi.org/10.1590/s2175-97902022e19193Keywords:
Drug utilization, Alendronate, Osteoporosis, PostmenopausalAbstract
The present study proposes and evaluates the test-retest reliability of indicators of the correct use of sodium alendronate in elderly patients. This is a test-retest reliability study for use of sodium alendronate. Six questions to evaluate the correct use of this medicine were elaborated after analysis of information in the literature. Data collection was performed through questionnaires in face-to-face in-home interviews by previously trained interviewers. The participants were initially interviewed (test) when they agreed to participate in the study, and secondly (retest), after a period of 7 to 14 days from the first interview. The reliability of the questions was evaluated by means of the agreement percentage and the Kappa coefficient. Fifty-seven pairs (test-retest) were obtained. The mean age was 69.3 (SD = 6.9) years, the majority (92.5%) completed elementary education, and declared themselves white (50.9%). All the questions presented high concordance ranging from 79.0% to 98.3%. The Kappa values ranged from 0.1 (low) to 0.83 (very good). The agreement percentage and the Kappa values suggest adequate reliability of the proposed questions. We suggest that they can be used as a simple and quick way to evaluate the quality of sodium alendronate use among the elderly.
Downloads
References
Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
Aquino EML, Araujo MJ, Almeida MCC, Conceição P, Andrade CR, Cade, NV, et al. Recrutamento de participantes no Estudo Longitudinal de Saúde do Adulto. Rev Saúde Pública. 2013;47(Supl 2):10-8.
Camargo EP, Minosso M, Lopes LC. Caracterização do uso de alendronato de sódio no tratamento de osteoporose por clínicos da rede privada de duas cidades do interior de São Paulo. Rev Ciênc Farm Básica Apl. 2007;28(1)77-83.
Escher A, Coutinho T. Uso racional de medicamentos, farmaceuticalização e usos do metilfenidato. Ciênc Saúde Coletiva. 2017;22:2571-2580.
Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43(6):543-9.
Fontes TMP, Araujo LFB, Soares PRG. Osteoporose no climatério I: epidemiologia, definição, rastreio e diagnóstico. Femina. 2012;40(2):109-116.
Griep RH, Chor D, Faerstein E, Lopes C. Confiabilidade teste-reteste de aspectos da rede social no Estudo Pró-Saúde. Rev. Saúde Pública. 2003;37(3):379-85.
Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. United Kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract. 1998;48(429):1161-1162.
Mahamood A, Elneour AA, Ali AAA, Hassan N, Shehab A, Bhagavathula AS. Evaluation of rational use of medicines (RUM) in four government hospitals in UAE. Saudi Pharm J. 2016;24(2):189-196.
Martins GA. Sobre confiabilidade e validade. Rev Bras Gestão Negócios. 2006;8(20):1-12.
Mata PR, Martins PA, Brito LG, Ramos MMP, Junior MCS. Tratamento farmacológico para a osteoporose. Rev Bras Geriatr Gerontol. 2012;6(4)422-431.
Pilatti L.A, Pedroso B, Gutierrez G.L. Propriedades Psicométricas de Instrumentos de Avaliação: Um debate necessário. Rev Bras Ensino Cienc Tecnol. 2010;3(1):81-91.
Pilger C, Menon MH, Mathias TAF. Características sociodemográficas e de saúde de idosos: contribuições para os serviços de saúde. Rev Latino-Am Enfermagem. 2011;19(5):1-12.
Pinheiro RS, Viacava F, Travassos C, Brito AS. Gênero, morbidade, acesso e utilização de serviços de saúde no Brasil. Ciênc Saúde Colet. 2002;7(4):687-707.
Radominski SC, Bernardo W, Paula AP, Albergaria BH, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós- menopausa. Rev Bras Reumatol. 2017;57(S2):S452-S466.
Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651-657.
WHO - World Health Organization. Perspectivas políticas de la OMS sobre medicamentos. Promoción del uso racional de medicamentos: componentes centrales [Internet] Genebra: OMS; 2002 [citad 2018 Nov 11]. Available from: Available from: http://apps.who.int/medicinedocs/pdf/s4874s/s4874s.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
